Warfarin therapy: How the less interesting half just got interesting

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2705-2707

  Miller, G P ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIMETIDINE; CYTOCHROME P450 2C9; DEXAMETHASONE; DRUG METABOLITE; GEFITINIB; OMEPRAZOLE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TOLBUTAMIDE; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; DRUG COMPETITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE CONTROL; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ACETAMINOPHEN; ANTICOAGULANTS; AZITHROMYCIN; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; OMEPRAZOLE; QUINAZOLINES; STEREOISOMERISM; SUBSTRATE SPECIFICITY; WARFARIN;

EID: 78650035571     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04097.x     Document Type: Article

References (27)

1. Rathbun S. Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation 2009; 119: e480-2.
2. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30.
3. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
4. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
5. Rulcova A, Prokopova I, Krausova L, Bitman M, Vrzal R, Dvorak Z, Blahos J, Pavek P. Stereoselective interactions of warfarin enantiomers with pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost 2010; 8: 2708-17.
6. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177: 369-71.
7. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239-82.
8. Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem 2009; 16: 3480-675.
9. Onoda S, Mitsufuji H, Yanase N, Ryuge S, Kato E, Wada M, Ishii K, Hagiri S, Yamamoto M, Yokoba M, Yanaihara T, Kuboto M, Takada N, Katagiri M, Abe T, Tanaka N, Kobayashi H, Masuda N. Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 2005; 35: 478-82.
10. Lehmann D. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy 2000; 20: 1464-8.
11. Kunze K, Eddy AC, Gibaldi M, Trager WF. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 1991; 3: 24-9.
12. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 2010; 23: 939-45.
13. Mahe I, Caulin C, Bergmann JF. Does paracetamol potentiate the effects of oral anticoagulants?: a literature review. Drug Saf 2004; 27: 325-33.
14. Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39: 11-21.
15. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 2009; 37: 1611-21.
16. Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res 2010; 44: 340-55.
17. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 2005; 20: 653-6.
18. Von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
19. Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med 1979; 90: 348-9.
20. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65: 369-76.
21. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, Sano H. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31: 1-10.
22. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13: 3731-7.
23. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-18.
24. Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 2008; 30: 276-81.
25. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84.
26. Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K, Yamazoe Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol 2008; 76: 139-45.
27. Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab 2005; 6: 399-411.